One in 10 people suffer from one or several of the 80 distinct chronic autoimmune disease, or immune-mediated inflammatory disease (IMID), ranging from the more common plaque psoriasis, rheumatoid arthritis or Crohn's disease to orphan diseases like systemic sclerosis or sarcoidosis.
There is a clear unmet medical need with the available drugs failing to successfully treat many of these patients to disease remission.
OUR INNOVATIVE TECHNOLOGY
Methotrexate is the 1st line, cornerstone drug treatment to treat most of the chronic autoimmune disease. Methotrexate has held this place as first choice, because of its good safety profile. And in about 1/3 of the patients, it works really well as a mono-therapy. However, in the majority of the patients, other drugs are added to obtain disease remission. For Methotrexate to become optimally effective, it needs to be retained in the pro-inflammatory cells long enough to be poly-glutamated by intracellular enzymes.
With our proprietary NovoBioMed technology we trap drugs in the cells by transiently blocking their elimination via the ABCG2 gate. The result: with a lower overall drug dose we can reach higher intracellular levels of the activated drug faster.
With our innovative and insightful technology, we strive to enhance patients’ every day quality of life.
Founded in 2021. Get in touch to learn more.
THE TEAM BEHIND AMPLIO PHARMA
To develop new drug product a comprehensive team of experts is needed!
For NovoBioJect, we have been able to recruit an international advisory teams of experts bringing the necessary expertise from all the areas needed to successfully develop a drug product, including leading rheumatologists.
"We firmly believe, that the effort to amplify the efficacy/safety of methotrexate through the addition of an ABCG2 PK-enhancer and the repurposing of the natural compound novobiocin, is in very capable hands"- M. Mensonides-Harsema, CEO Amplio Pharma BV.
CEO
Chief Scientific Officer, Clinical
Chief Scientific Officer, Non-Clinical
Chief Stragegy Officer
OUR CRO-PARTNERS
For NovoBioJect to come to the market, it has to go through a clinical development program and demonstrate superiority over the current drug products with methotrexate. Because we have chosen our PK enhancer in a smart and sustainable way, we already know a lot about the clinical behavior of NovoBioJect and we have shown that in pre-clinical models, NovoBioJect delivers what it promises: an elongated elimination of methotrexate from the system!
​
Together with the Department Laboratory Medicine of the Amsterdam UMC, the Academic Pharma group of the LUMC, the phase 1 clinic of Leiden (CHDR) and the rheumatology group of the LUMC, the GMP-qualified analysis lab BrightLabs, and OctoRelease (QP and DRA CRO), we are now getting ready for the human proof-of-principle study, which will test the hypothesis of NovoBioJect in patients with rheumatoid arthritis.
OUR INVESTORS
GET IN TOUCH
Amplio Pharma BV
Hulstweg 11, PB1
1032 LB Amsterdam, the Netherlands
©2020 by Amplio Pharma BV. Proudly created with Wix.com